TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

23.15

+0.60 (+2.66%)

As of 1:06PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	22.55
Open	22.54
Bid	23.15 x 100
Ask	23.21 x 100
Day's Range	22.50 - 23.44
52 Week Range	21.27 - 43.44
Volume	114,452
Avg. Volume	267,456

Market Cap	1.269B
Beta	1.49
PE Ratio (TTM)	N/A
EPS (TTM)	-5.45
Earnings Date	Aug 7, 2017 - Aug 11, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	36.25

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswireyesterday
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 - 78.8% for Obese and Elderly Patient Subgroups Additional Study ...
PR Newswire4 days ago
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
PR Newswire5 days ago
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
DUBLIN, April 19, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease (COPD). The IMPACT study is one of the largest trials ever conducted in COPD patients with a history of exacerbation.1 Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
PR Newswire7 days ago
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor ...
Markit14 days ago
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Simply Wall St.25 days ago
Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?
Theravance Biopharma Inc (NASDAQ:TBPH), a pharmaceuticals company based in Cayman Islands, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
Zacks26 days ago
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR Newswirelast month
Theravance Biopharma to Present at the 17th Annual Needham Healthcare Conference
DUBLIN, March 21, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 9:00 a.m. ET. The conference will be held from March 27 - 28 at the Westin Grand Central Hotel in New York. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
Market Realistlast month
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.
Markit2 months ago
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Thomson Reuters StreetEvents2 months ago
Edited Transcript of TBPH earnings conference call or presentation 27-Feb-18 10:00pm GMT
Q4 2017 Theravance Biopharma Inc Earnings Call
Zacks2 months ago
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
Associated Press2 months ago
Theravance Bio reports 4Q loss
The George Town, Cayman Islands-based company said it had a loss of $1.64 per share. The biopharmaceutical company posted revenue of $4.5 million in the period. For the year, the company reported that ...
PR Newswire2 months ago
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Multiple Programs Poised to Advance in 2018 DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported ...
ACCESSWIRE2 months ago
Theravance Biopharma Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Theravance Biopharma Inc NASDAQ: TBPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 5:00 PM Eastern ...
Benzinga2 months ago
Theravance Biopharma Q4 Earnings Outlook
Don't be caught off-guard: Theravance Biopharma (NASDAQ: TBPH ) releases its next round of earnings Tuesday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
Markit2 months ago
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Motley Fool2 months ago
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Johnson & Johnson has had huge success with small deals in the past. Here's a look at the latest bet.
PR Newswire2 months ago
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018. An accompanying conference call will be held at 5:00 pm ET on February 27, 2018. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 3999284. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through March 29, 2018.
PR Newswire2 months ago
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
DUBLIN, Feb. 15, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
ACCESSWIRE2 months ago
Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473
Stock Monitor: Enanta Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on Theravance Biopharma, Inc. (NASDAQ: TBPH ...
Zacks2 months ago
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
24/7 Wall St.2 months ago
Why Theravance Biopharma Shares Are Soaring
Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.
PR Newswire2 months ago
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
DUBLIN, Feb. 7, 2018 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today announced that it has entered into a global co-development and commercialization agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Under the terms of the agreement, Theravance Biopharma will receive an upfront payment of $100 million and will be eligible to receive up to an additional $900 million in potential payments, if Janssen elects to remain in the collaboration following the completion of certain Phase 2 activities, as described below.
Markit3 months ago
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH